Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

SANOFI : Combined General Shareholder Meeting of May 4, 2012

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/04/2012 | 07:35pm CEST
PRESS RELEASE Combined General Shareholder Meeting of May 4, 2012

? Shareholder approval of the corporate and consolidated financial statements for 2011

? Dividend of ?2.65 per share payable as of May 15, 2012

? Nomination of a new director

? Partial renewal of the Board of Directors

Paris, France - May 4, 2012 - Sanofi (EURONEXT : SAN et NYSE : SNY) announced its Combined General Shareholder Meeting was held today at the Palais des Congrès in Paris. All resolutions were adopted by its shareholders.

During the meeting, shareholders approved, among other resolutions, the corporate and consolidated financial statements for the year 2011. At the General Meeting, shareholders decided the distribution of a dividend in the amount of ?2.65 per share that will be detached on Euronext Paris on May 10, 2012 with payment as of May 15, 2012.
The General Meeting also approved the appointment of Mr. Laurent Attal as a director for a term of four years, i.e., until the General Meeting called to approve the financial statements for the year
2015. Finally, Mr. Uwe Bicker, Mr. Jean-René Fourtou, Ms. Claudie Haigneré, Ms. Carole Piwnica and Mr. Klaus Pohle have each been reappointed for a term of four years.
After the Shareholder Meeting, the Board of Directors is comprised as follows:

? Serge Weinberg, Chairman of the Board of Directors

? Christopher Viehbacher, Chief Executive Officer

? Laurent Attal

? Uwe Bicker

? Robert Castaigne

? Thierry Desmarest

? Lord Douro

? Jean-René Fourtou

? Claudie Haigneré

? Igor Landau

? Suet-Fern Lee

? Christian Mulliez

? Carole Piwnica

? Klaus Pohle

? Gérard Van Kemmel

During the meeting, the shareholders approved the appointment of statutory and deputy auditors. The shareholders additionally ratified the move of the registered headquarters of Sanofi to 54, rue La Boétie, 75008 Paris. During the Board of Directors session following the meeting, Mr. Klaus Pohle was renewed as Chairman of the Audit Committee.

1/2

The voting results will be available on the company's website (www.sanofi.com) in the coming days.
The audiocast of the Combined General Shareholder Meeting is available on the Company's website (www.sanofi.com).

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Contacts:

Media Relations Investor Relations

Jean-Marc Podvin Sébastien Martel

+ (33) 1 53 77 46 46 + (33) 1 53 77 45 45 [email protected] [email protected]

2/2

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
05/25 SANOFI : Data on Influenza Described by Researchers at Sanofi (Passive enhanced ..
05/25 ALNYLAM PHARMACEUTICALS, INC. (NASDA : ALNY) Files An 8-K Entry into a Material ..
05/25 SANOFI : FDA approves Sanofi and Regenerons Kevzara for adult rheumatoid arthrit..
05/24 SANOFI : Regeneron RA Drug Kevzara Wins FDA Approval
05/23 SANOFI : and Regeneron Announce FDA Approval of Kevzara (Sarilumab) for the Trea..
05/23 THE BUSINESS RESEARCH COMPANY : Asia accounted for $307 billion in the pharmaceu..
05/23 SANOFI : s insulin lispro receives CHMP positive opinion to treat diabetes
05/23 SANOFI : Phony Veterinary Labels Land Michael Chihwen Wang in the Doghouse
05/22 SANOFI : and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Tre..
05/22 SANOFI SA : Blog Coverage: CHMP Okays French Pharma Major Sanofi's Insulin Lispr..
More news
Sector news : Pharmaceuticals - NEC
06:49p WARREN BUFFETT : Warren Buffett takes 3 percent stake in Germany's Lanxess
06:41pDJMERCK : Congo Approves Anti-Ebola Vaccine to Combat Outbreak in Remote Northeast
05/26DJSUN PHARMACEUTICAL INDUSTRIES : Pharma 4Q Profit Falls 13.6%
05/24 JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
05/24 FTSE edges up helped by M&S, but miners weigh
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01:50a VALEANT : Heading To Single Digits Again?
05/25 FDA drug approvals rebound from last year, up over 100% yoy
05/25 FDA chief says agency needs to play a role in constraining drug prices by eas..
05/24 Exelixis Could Still Be A Buy
05/24 3 THINGS IN BIOTECH YOU SHOULD LEARN : May 24, 2017 - FDA Makes History
Advertisement
Financials (€)
Sales 2017 36 691 M
EBIT 2017 9 442 M
Net income 2017 7 526 M
Debt 2017 3 541 M
Yield 2017 3,42%
P/E ratio 2017 14,83
P/E ratio 2018 18,18
EV / Sales 2017 3,11x
EV / Sales 2018 2,99x
Capitalization 110 539 M
More Financials
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 85,6 €
Spread / Average Target -2,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI13.54%123 549
JOHNSON & JOHNSON10.16%341 901
ROCHE HOLDING LTD.14.62%236 581
NOVARTIS AG6.07%211 457
PFIZER INC.-1.05%191 398
MERCK & CO., INC.10.28%177 567
More Results